These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27730066)

  • 21. Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years.
    Li Q; Ganguly R; Ganz ML; Gamble C; Dang-Tan T
    Diabetes Ther; 2018 Jun; 9(3):1279-1293. PubMed ID: 29744818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of liraglutide after three years of treatment.
    Ponzani P; Scardapane M; Nicolucci A; Rossi MC
    Minerva Endocrinol; 2016 Mar; 41(1):35-42. PubMed ID: 26878560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective Analysis of an Insulin-to-Liraglutide Switch in Patients with Type 2 Diabetes Mellitus.
    Bruinstroop E; Meyer L; Brouwer CB; van Rooijen DE; van Dam PS
    Diabetes Ther; 2018 Jun; 9(3):1369-1375. PubMed ID: 29779196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States.
    Langer J; Hunt B; Valentine WJ
    J Manag Care Pharm; 2013 Apr; 19(3):237-46. PubMed ID: 23537458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial.
    de Wit HM; Vervoort GM; Jansen HJ; de Galan BE; Tack CJ
    J Intern Med; 2016 Mar; 279(3):283-92. PubMed ID: 26553486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes.
    Mosikian AA; Golikova TI; Martjanova MV; Babenko AY
    Future Sci OA; 2022 Mar; 8(3):FSO779. PubMed ID: 35251693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Liraglutide in clinical practice: Single centre experience.
    Rashid MO; Jabeen S; Khoja A; Islam N
    Pak J Med Sci; 2020; 36(3):432-437. PubMed ID: 32292448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study.
    Nikolic D; Patti AM; Giglio RV; Chianetta R; Castellino G; Magán-Fernández A; Citarrella R; Papanas N; Janez A; Stoian AP; Rizvi AA; Rizzo M
    Diabetes Ther; 2022 Mar; 13(3):453-464. PubMed ID: 35167051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world Effectiveness of Liraglutide vs. Sitagliptin Among Older Patients with Type 2 Diabetes Enrolled in a Medicare Advantage Prescription Drug Plan: A Retrospective Observational Study.
    Dang-Tan T; Kamble PS; Meah Y; Gamble C; Ganguly R; Horter L
    Diabetes Ther; 2020 Jan; 11(1):213-228. PubMed ID: 31820328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.
    Yamamoto T; Fukui T; Higuchi A; Ohara M; Hayashi T; Hirano T
    Diabetol Int; 2016 Dec; 7(4):425-431. PubMed ID: 30603295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
    Lorenzi M; Ploug UJ; Langer J; Skovgaard R; Zoratti M; Jansen J
    Diabetes Ther; 2017 Feb; 8(1):85-99. PubMed ID: 27995594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and psychological characteristics of liraglutide treatment among patients with type 2 diabetes.
    Al Hayek AA; Al Dawish MA
    J Family Med Prim Care; 2020 Feb; 9(2):1065-1071. PubMed ID: 32318468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia.
    Albarkah YA; Tourkmani AM; Bin Rsheed AM; Al Harbi TJ; Ebeid YA; Bushnag RA
    J Family Med Prim Care; 2019 Jun; 8(6):1919-1924. PubMed ID: 31334156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide Effectiveness in Type 2 Diabetes: Insights from a Real-World Cohort of Portuguese Patients.
    Silva-Nunes J; Nascimento E; Louro J; Dores J; Laginha T; Gonçalves-Ferreira A; Alves M; Souto SB; Cunha N; Pina E; Duarte R; Raposo JF
    Metabolites; 2022 Nov; 12(11):. PubMed ID: 36422260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study.
    Mezquita-Raya P; Reyes-Garcia R; Moreno-Perez O; Escalada-San Martin J; Ángel Rubio Herrera M; Lopez de la Torre Casares M
    Diabetes Ther; 2015 Jun; 6(2):173-85. PubMed ID: 26055216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial.
    Bashier AM; Hussain AA; Abdelgadir EI; Eltinay AT; Thadani P; Abdalla ME; Abusnana S; AlAwadi FF
    J Diabetes Metab Disord; 2015; 14():48. PubMed ID: 26064864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study.
    Yoo JH; Cho YK; Lee J; Kim HS; Kang YM; Jung CH; Park JY; Lee WJ
    Diabetes Ther; 2019 Aug; 10(4):1453-1463. PubMed ID: 31240562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.